Lung Cancer, Survivors (RELAX) (WF01213)

For a patient to be eligible for participation in this study, all of the following criteria must apply.

• Histologic or cytologic diagnosis of primary non-small cell Stage 0-II lung cancer,
• 2- 24 months post-completion of surgery, radiation therapy and/or chemotherapy with no further planned treatment during the 8-week study
• Score of ≥8 on the anxiety subscale of the HADS1
• Eastern Cooperative Oncology Group performance status 0-2
• Hemoglobin ≥9.5
• Smoking status anticipated to be stable during the study
• Willing/able to attend brief introductory session and use assigned device for the assigned period of time (15 minutes once or twice per day), 5 days per week for 8 weeks.
• Age ≥18 years

A patient will not be eligible for participation in this study if any of the following criteria apply.

• Patient does not understand English
• Active lung infection
• Radiation pneumonitis currently being treated with oral steroids
• Unstable angina
• Pulmonary embolism in past six months
• Progressive cancer (must be considered no evidence of disease or stable)
• Active suicidal ideation with plan or intent
• Any change in psychotropic medications in past month
• Hearing loss that would preclude participating in interventions.

To learn more, visit ClinicalTrials.Gov

Study Type

Phase: N/A

Principal Investigator(s)

Patricia Griffin, MD

Sponsor(s)

Wake Forest University Health Sciences